Novel GCGR/GLP-1R Dual Agonist TB001 Shows Promise for Treating Kidney Fibrosis
Key Insights
A novel dual agonist TB001 targeting both GCGR and GLP-1R (search) significantly improved kidney histopathology and reduced collagen deposition in a mouse model of renal fibrosis (search).
TB001 treatment effectively inhibited tubular cell epithelial-mesenchymal transition (EMT), a key process in kidney fibrosis (search) development, both in laboratory and animal studies.
The therapeutic mechanism appears to involve suppression of PERK (search)-mediated endoplasmic reticulum stress, offering new insights into potential treatment pathways for chronic kidney disease (search).
Researchers have demonstrated that TB001, a novel dual agonist targeting both glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R (search)), effectively reduces kidney fibrosis (search) in preclinical models. The study, conducted by teams from Sun Yat-sen University (search) and Southern University of Science and Technology (search), provides new evidence for targeting multiple metabolic pathways in treating chronic kidney disease (search) (CKD).
Addressing a Critical Healthcare Challenge
Chronic kidney disease (search) affects over one million individuals worldwide and represents a significant economic and healthcare burden. Renal fibrosis (search) serves as the hallmark of CKD progression, making effective anti-fibrotic therapies a critical unmet medical need. While previous reports have shown that GLP-1R (search) agonists can help prevent kidney fibrosis (search) in diabetic patients, the potential of dual receptor targeting has remained largely unexplored.
Comprehensive Preclinical Evaluation
The research team employed both in vitro and in vivo approaches to evaluate TB001's therapeutic potential. Using the unilateral ureteral obstruction (UUO) model in adult B6 mice, researchers established a well-validated system for studying kidney fibrosis (search). UUO mice received daily TB001 treatment post-surgery and were evaluated at day 14, with tissue samples collected for comprehensive analysis including immunohistochemistry and kidney mRNA gene expression profiling.
For in vitro studies, the team used mouse tubular epithelial cells (mTECs) stimulated with TGF-β to model kidney fibrosis (search) at the cellular level, allowing for detailed mechanistic investigations.
Significant Therapeutic Benefits
TB001 treatment demonstrated substantial improvements across multiple measures of kidney health. Compared with vehicle treatment, TB001 significantly improved renal histopathology and reduced interstitial collagen deposition, a key marker of fibrotic progression. The treatment also notably decreased macrophage infiltration in obstructed kidneys, suggesting anti-inflammatory effects alongside direct anti-fibrotic activity.
Both laboratory and animal studies confirmed that TB001 treatment significantly inhibited tubular cell epithelial-mesenchymal transition (EMT), a critical pathological process where epithelial cells lose their characteristics and acquire mesenchymal properties, contributing to fibrosis development.
Novel Mechanistic Insights
The study revealed that TB001's protective effects may operate through suppression of PERK (search)-mediated endoplasmic reticulum (ER) stress. Obstructed kidneys in the TB001 treatment group showed significantly fewer PERK and p-eIF2α positive cells compared to vehicle-treated controls, indicating reduced ER stress signaling.
These findings were corroborated by in vitro results demonstrating that TB001 significantly suppressed the expression of PERK (search) and CHOP, key ER stress markers, while enhancing mitochondrial mass during TGF-β-induced EMT. This dual effect on ER stress reduction and mitochondrial preservation suggests TB001 may address multiple cellular dysfunction pathways simultaneously.
Clinical Implications and Future Directions
The dual targeting approach represented by TB001 offers potential advantages over single-receptor therapies. By simultaneously engaging both GCGR and GLP-1R (search) pathways, TB001 may provide enhanced therapeutic efficacy while potentially reducing the risk of compensatory pathway activation that can limit single-target interventions.
The identification of PERK (search)-mediated ER stress as a key mechanism also opens new avenues for understanding how metabolic receptor agonists can influence kidney fibrosis (search) beyond their traditional roles in glucose homeostasis. This mechanistic insight may inform the development of additional therapeutic strategies targeting cellular stress responses in kidney disease.
The research provides compelling preclinical evidence that TB001 represents a promising therapeutic candidate for treating renal fibrosis (search), with the potential to address the significant unmet medical need in chronic kidney disease (search) management through its novel dual-receptor targeting approach and unique anti-fibrotic mechanisms.